Skip to main content
Canada’s most-awarded newsroom for a reason
Enjoy unlimited digital access
per week
for 24 weeks
Canada’s most-awarded newsroom for a reason
per week
for 24 weeks
// //

Johnson & Johnson NYSE: JNJ-N

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Today's Trading

Day Low 159.20
Day High 160.89
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.


Market Capitalization, $K
Shares Outstanding, K
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio


Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.

Moderate Buy


A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.


What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.


A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest Press Releases

Surgical Sealants and Adhesives Market - Latest Innovative Ideas to Guide to the Industry Growth, Key Players 2020-2026
- Heraldkeepers - Mon Oct 18, 12:46PM CDT
Heraldkeepers - CMTX
Mon Oct 18, 12:46PM CDT
The are segmented on the lines of its application, product, indication and regional. Based on application segmentation it covers central nervous system (CNS) surgeries, general surgeries, cardiovascular surgeries, orthopedic surgeries, cosmetic surgeries, urological surgeries, pulmonary surgeries, ophthalmic surgeries, other applications. Based on product segmentation it covers natural/biological sealants and adhesives, synthetic and semi-synthetic sealants and adhesives. Based on indication segmentation it covers surgical hemostasis, tissue sealing, tissue engineering. The Surgical Sealants and Adhesives Market on geographic segmentation cover various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geographic market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.
Johnson & Johnson COVID-19 Vaccine Booster Shot Unanimously Recommended for Emergency Use Authorization by U.S. FDA Advisory Committee
- PR Newswire - PRF - Fri Oct 15, 3:12PM CDT
PR Newswire - PRF - CMTX
Fri Oct 15, 3:12PM CDT
/PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted 19-0 to recommend Emergency Use Authorization (EUA) for a booster dose of the Johnson & Johnson COVID-19 vaccine for adults aged 18 and older at least two months following initial vaccination with the single-shot vaccine.
Johnson & Johnson Ovarian Cancer Victims Vow Fight to Stop J&J's Bankruptcy Scheme
- PR Newswire - PRF - Thu Oct 14, 9:38PM CDT
PR Newswire - PRF - CMTX
Thu Oct 14, 9:38PM CDT
/PRNewswire/ -- Lawyers who represent more than 30,000 women who have filed lawsuits against Johnson & Johnson (NYSE:JNJ) in connection with its defective talc body powders, including the iconic Johnson's Baby Powder, say they will resist J&J's decision to use bankruptcy to avoid legal responsibility for the cancers tied to those products.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 157.34 +1.77% increase
on 10/12/21
Period Open:164.75
Price movement based on the high, low and last over the given period.
165.98 -3.53% decrease
on 09/21/21
-4.63 (-2.81%) decrease
since 09/17/21
3-Month 157.34 +1.77% increase
on 10/12/21
Period Open:168.10
Price movement based on the high, low and last over the given period.
179.92 -11.00% decrease
on 08/20/21
-7.98 (-4.75%) decrease
since 07/16/21
52-Week 133.65 +19.81% increase
on 10/30/20
Period Open:148.10
Price movement based on the high, low and last over the given period.
179.92 -11.00% decrease
on 08/20/21
+12.02 (+8.12%) increase
since 10/16/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

© 2021 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies